Pharmaceutical group · India
Lupin
A group of 13 companies with 148 medicines in 6 countries.
Group structure
13 companies in 4 countries
Loading your page…
Loading your page…
Pharmaceutical group · India
A group of 13 companies with 148 medicines in 6 countries.
13 companies in 4 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1–25 of 148
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALLERNAZE0.05mg/spray · Spray, metered | Triamcinolone | United States | Not marketed | 2000 |
| AMABELZ0.5mg; 0.1mg | 1mg; 0.5mg · Tablet | Estradiol, Norethindrone | United States | Marketed | 2016 |
| ANTARA (MICRONIZED)130MG | 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 43MG | 87MG | 90MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule | Fenofibrate | United States | Marketed | 2004 |
| ARMLUPEG6mg/0.6ml · Injection | Pegfilgrastim | United States | Marketed | 2025 |
| ARMLUPEG6 mg / 0.6 ml · Solution | Pegfilgrastim | Canada | Authorised | |
| AZILSARTAN MEDOXOMIL40mg medoxomil | 80mg medoxomil · Tablet | Azilsartan kamedoxomil | United States | Marketed | 2022 |
| BEKYREE0.15mg,n/a; 0.02mg,0.01mg · Tablet | Desogestrel, N/a, Ethinyl estradiol | United States | Marketed | 2015 |
| BLISOVI 24 FE0.02mg; 1mg · Tablet | Ethinyl estradiol, Norethindrone | United States | Marketed | 2015 |
| BLISOVI FE 1/200.02mg; 1mg · Tablet | Ethinyl estradiol, Norethindrone | United States | Marketed | 2015 |
| BLISOVI FE 1.5/300.03mg; 1.5mg · Tablet | Ethinyl estradiol, Norethindrone | United States | Marketed | 2015 |
| BREXPIPRAZOLE0.25mg | 0.5mg | 1mg | 2mg | 3mg | 4mg · Tablet | Brexpiprazole | United States | Marketed | 2021 |
| BRIVARACETAM100mg | 100MG | 10MG | 25mg | 25MG | 50mg | 50MG | 75mg | 75MG · Tablet | Brivaracetam | United States | Marketed | 2022 |
| BROVANA0.015mg base/2ml · Solution | Arformoterol | United States | Not marketed | 2006 |
| CEFDINIR300mg · Capsule | Cefdinir | United States | Marketed | 2006 |
| CEFDINIR125mg/5ml | 250mg/5ml · For suspension | Cefdinir | United States | Marketed | 2006 |
| CLOBAZAM10mg | 20mg | 5mg · Tablet | Clobazam | United States | Marketed | 2018 |
| DAYSEE0.03mg,0.01mg; 0.15mg,n/a · Tablet | Ethinyl estradiol, Levonorgestrel, N/a | United States | Marketed | 2013 |
| DOXYCYCLINE25mg base/5ml · For suspension | Doxycycline | United States | Marketed | 2008 |
| DROSPIRENONE AND ETHINYL ESTRADIOL3mg; 0.03mg · Tablet | Drospirenone, Ethinyl estradiol | United States | Marketed | 2008 |
| DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM3mg,n/a; 0.02mg,n/a; 0.451mg,0.451mg | 3mg,n/a; 0.03mg,n/a; 0.451mg,0.451mg · Tablet | Drospirenone, N/a, Ethinyl estradiol, Levomefolate | United States | Marketed | 2016 |
| EMTRICITABINA/TENOFOVIR ALAFENAMIDA LUPIN 200 MG/10 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG200 mg + 12,478 mg · Comprimido recubierto con película | Emtricitabine, Tenofovir alafenamide | Spain | Authorised | 2026 |
| EMTRICITABINA/TENOFOVIR ALAFENAMIDA LUPIN 200 MG/25 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG200 mg + 31,194 mg · Comprimido recubierto con película | Emtricitabine, Tenofovir alafenamide | Spain | Authorised | 2026 |
| EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE120mg; 15mg base | 200mg; 25mg base · Tablet | Emtricitabine, Tenofovir alafenamide | United States | Marketed | 2024 |
| Emtricitabine/Tenofoviralafenamide Lupin 200 mg/10 mg filmomhulde tablettenFilmomhulde tablet | Emtricitabine, Tenofoviralafenamidesuccinaat | Netherlands | Authorised | 2026 |
| Emtricitabine/Tenofoviralafenamide Lupin 200 mg/25 mg filmomhulde tablettenFilmomhulde tablet | Emtricitabine, Tenofoviralafenamidesuccinaat | Netherlands | Authorised | 2026 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 77 | 62 | 15 | CompaniesAll medicines |
| Canada | 49 | 47 | 2 | CompaniesAll medicines |
| Netherlands | 9 | 9 | 0 | CompaniesAll medicines |
| Spain | 8 | 7 | 1 | CompaniesAll medicines |
| European Union (EMA) | 3 | 2 | 1 | CompaniesAll medicines |
| Italy | 2 | 2 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, France, Singapore, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.